Literature Review of Omicron: A Grim Reality Amidst COVID-19
Abstract
:1. Background
2. Structural Characteristics of the Omicron
3. Virologic Characteristics Explained (Omicron vs. Delta Variant)
4. Epidemiology of Omicron and a Tropism Shift
5. Potential for Immune Escape
6. Laboratory Testing
7. Therapeutics
8. Public Health Response to Minimize Omicron Transmission
Author Contributions
Funding
Conflicts of Interest
References
- Centers for Disease Control and Prevention Transmission of Coronavirus Disease 2019 (COVID-19). Available online: https://www.cdc.gov/coronavirus/2019-ncov/index.html (accessed on 21 January 2022).
- Coronaviridae Study Group of the International Committee on Taxonomy of Viruses. The species Severe acute respiratory syndrome-related coronavirus: Classifying 2019-nCoV and naming it SARS-CoV-2. Nat. Microbiol. 2020, 5, 536–544. [Google Scholar] [CrossRef] [Green Version]
- Wax, R.S.; Christian, M.D. Practical recommendations for critical care and anesthesiology teams caring for novel coronavirus (2019-nCoV) patients. Can. J. Anesth. 2020, 67, 568–576. [Google Scholar] [CrossRef] [PubMed] [Green Version]
- The Worldometers. COVID-19 Coronavirus Pandemic. 2022. Available online: https://www.worldometers.info/coronavirus/ (accessed on 21 January 2022).
- Centers for Disease Control and Prevention. SARS-CoV-2 Variant Classifications and Definitions. 2021. Available online: https://www.cdc.gov/coronavirus/2019-ncov/variants/variant-info.html (accessed on 6 December 2021).
- Centers for Disease Control and Prevention. Omicron Variant: What You Need to Know. 2021. Available online: https://www.cdc.gov/coronavirus/2019-ncov/variants/omicron-variant.html (accessed on 31 December 2021).
- Boynton, S. When Will the Omicron Wave End? Data Suggests It Could Be Soon, but Experts Are Wary. Available online: https://globalnews.ca/news/8494760/omicron-wave-end-covid/ (accessed on 10 January 2022).
- Government of South Africa. Cabinet Approves Several Changes to the Adjusted Alert Level 1 COVID19 Regulations [Internet]. 2021. Available online: https://www.gov.za/speeches/cabinet-approves-several-changes-adjusted-alertlevel-1-covid-19-regulations-30-dec-2021 (accessed on 10 January 2022).
- World Health Organization. Update on Omicron 2021. Available online: https://www.who.int/news/item/28-11-2021-update-on-omicron (accessed on 6 December 2021).
- European Centre for Disease Prevention and Control. Epidemiological Update: Omicron Variant of Concern (VOC)-Data As of 11 December 2021. Available online: https://www.ecdc.europa.eu/en/news-events/epidemiological-update-omicron-variant-concern-voc-data-11-december-2021 (accessed on 21 January 2022).
- Liu, L.; Iketani, S.; Guo, Y.; Chan, J.F.-W.; Wang, M.; Liu, L.; Luo, Y.; Chu, H.; Huang, Y.; Nair, M.S.; et al. Striking Antibody Evasion Manifested by the Omicron Variant of SARS-CoV-2. Nature 2021. [Google Scholar] [CrossRef] [PubMed]
- Pulliam, J.R.C.; van Schalkwyk, C.; Govender, N.; von Gottberg, A.; Cohen, C.; Groome, M.J.; Dushoff, J.; Mlisana, K.; Moultrie, H. Increased risk of SARS-CoV-2 reinfection associated with emergence of the Omicron variant in South Africa. Medrxiv 2021. [Google Scholar] [CrossRef]
- McCreesh, N.; Dlamini, V.; Edwards, A.; Oliver, S.; Dayi, N.; Dikgale, K.; Nxumalo, S.; Dreyer, J.; Baisley, K.; Siedner, M.J.; et al. Impact of the COVID-19 epidemic and related social distancing regulations on social contact and SARS-CoV-2 transmission potential in rural South Africa: Analysis of repeated cross-sectional surveys. BMC Infect. Dis. 2021, 21, 928. [Google Scholar] [CrossRef] [PubMed]
- Mohiuddin, M.; Kasahara, K. Investigating the aggressiveness of the COVID-19 Omicron variant and suggestions for possible treatment options. Respir. Med. 2021, 191, 106716. [Google Scholar] [CrossRef] [PubMed]
- French, G.; Hulse, M.; Nguyen, D.; Sobotka, K.; Wedster, K.; Corman, J.; Aboagye-Nyame, B.; Dion, M.; Johnson, M.; Zalinger, B.; et al. Impact of Hospital Strain on Excess Deaths During the COVID-19 Pandemic-United States, July 2020–July 2021. MMWR Morb. Mortal. Wkly. Rep. 2021, 70, 1613–1616. [Google Scholar] [CrossRef]
- Kannan, S.R.; Spratt, A.N.; Sharma, K.; Chand, H.S.; Byrareddy, S.N.; Singh, K. Omicron SARS-CoV-2 variant: Unique features and their impact on pre-existing antibodies. J. Autoimmun. 2022, 126, 102779. [Google Scholar] [CrossRef]
- Lubin, J.H.; Markosian, C.; Balamurugan, D.; Pasqualini, R.; Arap, W.; Burley, S.K.; Khare, S.D. Structural models of SARS-CoV-2 Omicron variant in complex with ACE2 receptor or antibodies suggest altered binding interfaces. bioRxiv 2021, 12, 472313. [Google Scholar] [CrossRef]
- Saxena, S.K.; Kumar, S.; Ansari, S.; Paweska, J.T.; Maurya, V.K.; Tripathi, A.K.; Abdel-Moneim, A.S. Characterization of the novel SARS-CoV-2 Omicron (B.1.1.529) variant of concern and its global perspective. J. Med. Virol. 2021. [Google Scholar] [CrossRef]
- Mannar, D.; Saville, J.W.; Zhu, X.; Srivastava, S.S.; Berezuk, A.M.; Tuttle, K.S.; Marquez, A.C.; Sekirov, I.; Subramaniam, S. SARS-CoV-2 Omicron variant: Antibody evasion and cryo-EM structure of spike protein-ACE2 complex. Science 2022. [Google Scholar] [CrossRef]
- Kumar, S.; Thambiraja, T.S.; Karuppanan, K.; Subramaniam, G. Omicron and Delta variant of SARS-CoV-2: A comparative computational study of spike protein. J. Med. Virol. 2021. [Google Scholar] [CrossRef]
- Centers for Disease Control And Prevention. Science Brief: Omicron (B.1.1.529) Variant. 2021. Available online: https://www.cdc.gov/coronavirus/2019-ncov/science/science-briefs/scientific-brief-omicron-variant.html (accessed on 31 December 2021).
- Scialo, F.; Daniele, A.; Amato, F.; Pastore, L.; Matera, M.G.; Cazzola, M.; Castaldo, G.; Bianco, A. ACE2: The Major Cell Entry Receptor for SARS-CoV-2. Lung 2020, 198, 867–877. [Google Scholar] [CrossRef]
- Joseph, S.; Nair, B.; Nath, L.R. The Ineluctable Role of ACE-2 Receptors in SARS-CoV-2 Infection and Drug Repurposing as a Plausible SARS-CoV-2 Therapy: A Concise Treatise. Curr. Mol. Med. 2021, 21, 888–913. [Google Scholar] [CrossRef]
- Zhao, H.; Lu, L.; Peng, Z.; Chen, L.-L.; Meng, X.; Zhang, C.; Chan, W.-M.; Chu, A.W.-H.; Chan, K.-H.; Jin, D.-Y.; et al. SARS-CoV-2 Omicron variant shows less efficient replication and fusion activity when compared with Delta variant in TMPRSS2-expressed cells. Emerg. Microbes Infect. 2022, 11, 277–283. [Google Scholar] [CrossRef]
- Saito, A.; Irie, T.; Suzuki, R.; Maemura, T.; Nsaaer, H.; Uriu, K.; Kosugi, Y.; Shirakawa, K.; Sadamasu, K.; Kimura, I.; et al. Enhanced fusogenicity and pathogenicity of SARS-CoV-2 Delta P681R mutation. Nature 2021. [Google Scholar] [CrossRef]
- Youk, J.; Kim, T.; Evans, K.V.; Jeong, Y.-I.; Hur, Y.; Hong, S.P.; Kim, J.H.; Yi, K.; Kim, S.Y.; Na, K.J.; et al. Three-Dimensional Human Alveolar Stem Cell Culture Models Reveal Infection Response to SARS-CoV-2. Cell Stem Cell 2020, 27, 905–919. [Google Scholar] [CrossRef]
- Abbott, S.; Hellewell, J.; Thompson, R.N.; Sherratt, K.; Gibbs, H.P.; Bosse, N.I.; Munday, J.D.; Meakin, S.; Doughty, E.L.; Chun, J.Y.; et al. Estimating the time-varying reproduction number of SARS-CoV-2 using national and subnational case counts. Wellcome Open Res. 2020, 5, 112. [Google Scholar] [CrossRef]
- Song, W.J.; Hui, C.K.M.; Hull, J.H.; Birring, S.S.; Mcgarver, L.; Mazzone, S.B.; Chung, K.F. Confronting COVID-19-associated cough and the post-COVID syndrome: Role of viral neurotropism, neuroinflammation, and neuroimmune responses. Lancet Respir. Med. 2021, 9, 533–544. [Google Scholar] [CrossRef]
- Report from Norway. Available online: https://www.eurosurveillance.org/content/10.2807/1560-7917.ES.2021.26.50.2101147#f1 (accessed on 10 January 2022).
- UK Health Security Agency (UKHSA). SARS-CoV-2 Variants of Concern and Variants Under Investigation in England-Technical Briefing 31. 2021. Available online: https://assets.publishing.service.gov.uk/government/uploads/system/uploads/attachment_data/file/1040076/Technical_Briefing_31.pdf (accessed on 10 January 2022).
- Ibekwe, T.S.; Fasunla, A.J.; Orimadegun, A.E. Systematic Review and Meta-analysis of Smell and Taste Disorders in COVID-19. OTO Open 2020, 4, 2473974X20957975. [Google Scholar] [CrossRef]
- Hoffmann, M.; Kleine-Weber, H.; Schroeder, S.; Krüger, N.; Herrler, T.; Erichsen, S.; Schiergens, T.S.; Herrler, G.; Wu, N.-H.; Nitsche, A.; et al. SARS-CoV-2 Cell Entry Depends on ACE2 and TMPRSS2 and Is Blocked by a Clinically Proven Protease Inhibitor. Cell 2020, 181, 271–280. [Google Scholar] [CrossRef]
- Dong, M.; Zhang, J.; Ma, X.; Tan, J.; Chen, L.; Liu, S.; Xin, Y.; Zhuang, L. ACE2, TMPRSS2 distribution and extrapulmonary organ injury in patients with COVID-19. Biomed. Pharmacother. 2020, 131, 110678. [Google Scholar] [CrossRef]
- Maslo, C.; Friedland, R.; Toubkin, M.; Laubscher, A.; Akaloo, T.; Kama, B. Characteristics and Outcomes of Hospitalized Patients in South Africa During the COVID-19 Omicron Wave Compared with Previous Waves. JAMA 2021, 327, 583–584. [Google Scholar] [CrossRef]
- Burki, T.K. Omicron variant and booster COVID-19 vaccines. Lancet Respir. Med. 2021, 10, e17. [Google Scholar] [CrossRef]
- Poudel, S.; Ishak, A.; Perez-Fernandez, J.; Garcia, E.; León-Figueroa, D.A.; Romaní, L.; Bonilla-Aldana, D.K.; Rodriguez-Morales, A.J. Highly mutated SARS-CoV-2 Omicron variant sparks significant concern among global experts—What is known so far? Travel Med. Infect. Dis. 2021. [Google Scholar] [CrossRef]
- Ahmed, S.F.; Quadeer, A.A.; McKay, M.R. SARS-CoV-2 T Cell Responses Elicited by COVID-19 Vaccines or Infection Are Expected to Remain Robust against Omicron. Viruses 2022, 14, 79. [Google Scholar] [CrossRef]
- Wilhelm, A.; Widera, M.; Grikscheit, K.; Toptan, T.; Schenk, B.; Pallas, C.; Metzler, M.; Kohmer, N.; Hoehl, S.; Helfritz, F.A.; et al. Reduced neutralization of SARS-CoV-2 Omicron variant by vaccine sera and monoclonal antibodies. medRxiv 2021. [Google Scholar] [CrossRef]
- Roessler, A.; Riepler, L.; Bante, D.; von Laer, D.; Kimpel, J. SARS-CoV-2 Omicron Variant Neutralization in Serum from Vaccinated and Convalescent Persons. N. Engl. J. Med. 2022. [Google Scholar] [CrossRef]
- Planas, D.; Saunders, N.; Maes, P.; Guivel-Benhassine, F.; Planchais, C.; Buchrieser, J.; Bolland, W.-H.; Porrot, F.; Staropoli, I.; Lemoine, F.; et al. Considerable escape of SARS-CoV-2 Omicron to antibody neutralization. Nature 2021. [Google Scholar] [CrossRef]
- Krammer, F. A correlate of protection for SARS-CoV-2 vaccines is urgently needed. Nat. Med. 2021, 27, 1147–1148. Available online: https://www.nature.com/articles/s41591-021-01432-4 (accessed on 10 January 2022). [CrossRef]
- Hartley, G.E.; Edwards, E.S.; Aui, P.M.; Varese, N.; Stojanovic, S.; McMahon, J.; Peleg, A.Y.; Boo, I.; Drummer, H.E.; Hogarth, P.M.; et al. Rapid generation of durable B cell memory to SARS-CoV-2 spike and nucleocapsid proteins in COVID-19 and convalescence. Sci. Immunol. 2020, 5, eabf8891. Available online: https://immunology.sciencemag.org/content/5/54/eabf8891/43 (accessed on 10 January 2022). [CrossRef] [PubMed]
- Lau, E.H.; Tsang, O.T.; Hui, D.S.; Kwan, M.Y.; Chan, W.-h.; Chiu, S.S.; Ko, R.; Chan, K.H.; Cheng, S.; Perera, R.; et al. Neutralizing antibody titres in SARS-CoV-2 infections. Nat. Commun. 2021, 12, 1–7. Available online: https://www.nature.com/articles/s41467-020-20247-4 (accessed on 10 January 2022). [CrossRef]
- Cele, S.; Jackson, L.; Khoury, D.S.; Khan, K.; Moyo-Gwete, T.; Tegally, H.; San, J.E.; Cromer, D.; Scheepers, C.; Amoako, D.; et al. SARS-CoV-2 Omicron has extensive but incomplete escape of Pfizer BNT162b2 elicited neutralization and requires ACE2 for infection. medRxiv 2021. [Google Scholar] [CrossRef]
- Andrews, N.; Stowe, J.; Kirsebom, F.; Toffa, S.; Rickeard, T.; Gallagher, E.; Gower, C.; Kall, M.; Groves, N.; Connell, A.M.O’.; et al. Effectiveness of COVID-19 vaccines against the Omicron (B.1.1.529) variant of concern. medRxiv 2021. Available online: https://khub.net/documents/135939561/430986542/Effectiveness+of+COVID-19+vaccines+against+Omicron+variant+of+concern.pdf/f423c9f4-91cb-0274-c8c5-70e8fad50074 (accessed on 10 January 2022). [CrossRef]
- Barros-Martins, J.; Hammerschmidt, S.I.; Cossmann, A.; Odak, I.; Stankov, M.V.; Morillas Ramos, G.; Dopfer-Jablonka, A.; Heidemann, A.; Ritter, C.; Friedrichsen, M.; et al. Immune responses against SARS-CoV-2 variants after heterologous and homologous ChAdOx1 nCoV-19/BNT162b2 vaccination. Nat. Med. 2021, 27, 1525–1529. [Google Scholar] [CrossRef] [PubMed]
- Hoffmann, M.; Krüger, N.; Schulz, S.; Cossmann, A.; Rocha, C.; Kempf, A.; Nehlmeier, I.; Graichen, L.; Moldenhauer, A.S.; Winkler, M.S.; et al. The Omicron variant is highly resistant against antibody-mediated neutralization: Implications for control of the COVID-19. Cell 2021. [Google Scholar] [CrossRef] [PubMed]
- De Marco, L.; Dorso, S.; Pirronello, M.; Verdiani, A.; Termine, A.; Fabrizio, C.; Capone, A.; Sabatini, A.; Guerrera, G.; Placido, R.; et al. Preserved T cell reactivity to the SARS-CoV-2 Omicron variant indicates continued protection in vaccinated individuals. bioRxiv 2021. [Google Scholar] [CrossRef]
- Deerain, J.; Druce, J.; Tran, T.; Batty, M.; Yoga, Y.; Fennell, M.; Dwyer, D.E.; Kok, J.; Williamson, D.A. Assessment of the analytical sensitivity of ten lateral flow devices against the SARS-CoV-2 omicron variant. J. Clin. Microbiol. 2021. [Google Scholar] [CrossRef] [PubMed]
- Korukluoglu, G.; Kolukirik, M.; Bayrakdar, F.; Ozgumus, G.G.; Altas, A.B.; Cosgun, Y.; Ketre Kolukirik, C.Z. 40 minutes RT-qPCR Assay for Screening Spike N501Y and HV69-70del Mutations. bioRxiv 2021. [Google Scholar] [CrossRef]
- US Food and Drug Administration (FDA). SARS-CoV-2 Viral Mutations: Impact on COVID-19 Tests. 2021. Available online: https://www.fda.gov/medical-devices/coronavirus-covid-19-and-medical-devices/sars-cov2-viral-mutations-impact-covid-19-tests (accessed on 10 January 2022).
- World Health Organization. WHO Joint Advisory Group on COVID-19 Therapeutics Prioritization. 2021. Available online: https://www.who.int/publications/m/item/who-joint-advisory-group-on-covid-19-therapeutics-prioritization—draft-statement-on-the-possible-effects-of-the-new-sars-cov-2-omicron-variant-on-treatment-of-hospitalized-covid-19-patients (accessed on 24 January 2022).
- Cameroni, E.; Saliba, C.; Bowen, J.E.; Rosen, L.E.; Culap, K.; Pinto, D.; VanBlargan, L.A.; Marco, A.D.; Zepeda, S.K.; Iulio, J.D.; et al. Broadly neutralizing antibodies overcome SARS-CoV-2 Omicron Antigenic Shift. Nature 2021. [Google Scholar] [CrossRef]
- Aggarwal, A.; Stella, A.O.; Walker, G.; Akerman, A.; Milogiannakis, V.; Brilot, F.; Amatayakul-Chantler, S.; Roth, N.; Coppola, G.; Schofield, P.; et al. SARS-CoV-2 Omicron: Evasion of potent humoral responses and resistance to clinical immunotherapeutics relative to viral strains of concer. medRxiv 2021. [Google Scholar] [CrossRef]
- Centers for Disease Control and Prevention. CDC’S role in Tracking Variants. 2021. Available online: https://www.cdc.gov/coronavirus/2019-ncov/variants/cdc-role-surveillance.html (accessed on 24 January 2022).
Publisher’s Note: MDPI stays neutral with regard to jurisdictional claims in published maps and institutional affiliations. |
© 2022 by the authors. Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (https://creativecommons.org/licenses/by/4.0/).
Share and Cite
Arora, S.; Grover, V.; Saluja, P.; Algarni, Y.A.; Saquib, S.A.; Asif, S.M.; Batra, K.; Alshahrani, M.Y.; Das, G.; Jain, R.; et al. Literature Review of Omicron: A Grim Reality Amidst COVID-19. Microorganisms 2022, 10, 451. https://doi.org/10.3390/microorganisms10020451
Arora S, Grover V, Saluja P, Algarni YA, Saquib SA, Asif SM, Batra K, Alshahrani MY, Das G, Jain R, et al. Literature Review of Omicron: A Grim Reality Amidst COVID-19. Microorganisms. 2022; 10(2):451. https://doi.org/10.3390/microorganisms10020451
Chicago/Turabian StyleArora, Suraj, Vishakha Grover, Priyanka Saluja, Youssef Abdullah Algarni, Shahabe Abullais Saquib, Shaik Mohammed Asif, Kavita Batra, Mohammed Y. Alshahrani, Gotam Das, Rajni Jain, and et al. 2022. "Literature Review of Omicron: A Grim Reality Amidst COVID-19" Microorganisms 10, no. 2: 451. https://doi.org/10.3390/microorganisms10020451
APA StyleArora, S., Grover, V., Saluja, P., Algarni, Y. A., Saquib, S. A., Asif, S. M., Batra, K., Alshahrani, M. Y., Das, G., Jain, R., & Ohri, A. (2022). Literature Review of Omicron: A Grim Reality Amidst COVID-19. Microorganisms, 10(2), 451. https://doi.org/10.3390/microorganisms10020451